27 results on '"Harsh Parmar"'
Search Results
2. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
- Author
-
Alissa Visram, Abdullah S. Al Saleh, Harsh Parmar, Jennifer S. McDonald, John C. Lieske, Iuliana Vaxman, Eli Muchtar, Miriam Hobbs, Amie Fonder, Yi L. Hwa, Francis K. Buadi, David Dingli, Martha Q. Lacy, Angela Dispenzieri, Prashant Kapoor, Suzanne R. Hayman, Rahma Warsame, Taxiarchis V. Kourelis, Mustaqeem Siddiqui, Wilson I. Gonsalves, John A. Lust, Robert A. Kyle, S. Vincent Rajkumar, Morie A. Gertz, Shaji K. Kumar, and Nelson Leung
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract A 24-h urine protein collection (24hUP), the gold standard for measuring albuminuria in systemic AL amyloidosis, is cumbersome and inaccurate. We retrospectively reviewed 575 patients with systemic AL amyloidosis to assess the correlation between a urine albumin to creatinine ratio (uACR) and the 24hUP. The uACR correlated strongly with 24hUP at diagnosis (Pearson’s r = 0.87, 95% CI 0.83–0.90) and during the disease course (Pearson’s r = 0.88, 95% CI 0.86–0.90). A uACR ≥300 mg/g estimated a 24hUP ≥ 500 mg with a sensitivity of 92% and specificity of 97% (area under the receiver operating curve = 0.938, 95% CI 0.919–0.957). A uACR cutoff of 3600 mg/g best predicted a 24hUP > 5000 g (sensitivity 93%, specificity 94%), and renal stage at diagnosis was strongly concordant using either 24hUP or uACR as the proteinuria measure (k = 0.823, 95% CI 0.728–0.919). In patients with serial urine collections, a > 30% decrease in uACR predicted a > 30% decrease in 24hUP with a sensitivity of 94%. In conclusion, the uACR is a reliable and convenient method for ruling out proteinuria >500 mg per day, prognosticating renal outcomes, and assessing renal response to therapy. Further studies are needed to validate the uACR cutoffs proposed in this study.
- Published
- 2020
- Full Text
- View/download PDF
3. Knowledge, attitude, and practice toward social media use in dental education
- Author
-
Sayed Abrar, Harsh Parmar, Gulam Anwar Naviwala, Kishor Sapkale, Surabhi Nabazza, and Manoj M Ramugade
- Subjects
attitude ,dental education ,knowledge ,practice ,social media ,Dentistry ,RK1-715 - Abstract
Introduction: The use of social media has been a revolutionary way of communication, since the past decade. Considering its high level of usage among the younger individuals, social media may provide a unique method of learning for dental students. However, the perception of dental educators on the usage of social media and networking sites is unknown. Hence, this study was conducted to assess the knowledge, attitude, and practice of dental faculty and residents toward social media use in dental education. Materials and Methods: This cross-sectional study was conducted in Government Dental College and Hospital, Mumbai, from November 2019 to December 2019. The questionnaire was prepared and validated before conducting the study. All the faculty members and the residents of the college were included in the study. The questionnaire was based on three dimensions (knowledge, attitude, and practice) and assessed the views of participants on the social media usage. Results: A total of 65 participants were included in the study, where 32 were faculty members and 33 were residents. The mean age of the participants was 31.52 ± 6.589. Out of the total, 26 (40%) participants were male and 39 (60%) were female. The mean experience of the study participants was 4.71 ± 5.997. The responses were compared between residents and faculty and the responses were similar for most knowledge, attitude, and practice question. The residents were keener on looking forward to developing social media as a primary aid in dental education compared to the faculty (P = 0.029). Conclusion: Due to ease of use and widespread applicability, social media now has a great potential to deliver educational content. This study demonstrates the positive responses of the faculty towards social media usage and further enhances traditional education.
- Published
- 2020
- Full Text
- View/download PDF
4. Interaction between age and gender on survival outcomes in extramedullary multiple myeloma over the past two decades
- Author
-
Ayrton I Bangolo, Pierre Fwelo, Chinmay Trivedi, Sowmya Sagireddy, Hamed Aljanaahi, Auda Auda, Maryama Mohamed, Sonia Onyeka, Miriam Fisher, Jyoti Thapa, Erwin J Tabucanon, Lyuben Georgiev, Annetta Wishart, Shilpee Kumari, Conrad Erikson, Mary Bangura, Orent Paddy, Rashmi Madhukar, Eugenio L Gomez, Joshua Rathod, Mansi Naria, Basel Hajal, Mohammad Awadhalla, David Siegel, Harsh Parmar, Noa Biran, David H Vesole, Pooja Phull, and Simcha Weissman
- Subjects
Oncology - Published
- 2023
5. Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis
- Author
-
David Dingli, Eli Muchtar, Taxiarchis Kourelis, Alissa Visram, Abdullah S. Al Saleh, Ronald S. Go, Martha Q. Lacy, Francis K. Buadi, Shaji Kumar, Harsh Parmar, Prashant Kapoor, S. Vincent Rajkumar, Morie A. Gertz, Robert A. Kyle, Rahma Warsame, Suzanne R. Hayman, Nelson Leung, Angela Dispenzieri, and Wilson I. Gonsalves
- Subjects
Oncology ,Alkylating Agents ,Cancer Research ,medicine.medical_specialty ,Newly diagnosed ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Retrospective analysis ,medicine ,Humans ,In patient ,Multiple myeloma ,Aged ,Retrospective Studies ,Very Good Partial Response ,business.industry ,Retrospective cohort study ,Hematology ,medicine.disease ,Regimen ,Treatment Outcome ,Proteasome inhibitor ,Multiple Myeloma ,business ,medicine.drug - Abstract
This is a retrospective study of patients with multiple myeloma (MM) who were >75 years old. We identified 394 patients and for non-trial patients (n = 350), immunomodulatory drug (IMiD)+dex (32%) was the most commonly used regimen followed by alkylator with steroids or other therapy (21%), alkylator + proteasome inhibitor (PI)+steroid (18%), and IMiD + PI + dex (13%). Overall, achieving ≥ very good partial response was more in patients receiving a triplet compared to other therapies (46% vs. 21%, p 75 years old.
- Published
- 2021
6. From VAD to VRD
- Author
-
Harsh Parmar, Noa Biran, and David H. Vesole
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Standard of care ,business.industry ,medicine.medical_treatment ,Hematopoietic Stem Cell Transplantation ,MEDLINE ,Hematopoietic stem cell transplantation ,Newly diagnosed ,medicine.disease ,Transplantation, Autologous ,Transplantation ,Autologous stem-cell transplantation ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Multiple Myeloma ,business ,Multiple myeloma - Abstract
High-dose therapy followed by autologous stem cell transplantation (ASCT) is considered the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (MM). With new treatment combinations offering the advantage of improved clinical outcomes of MM patients, the utilization of ASCT is again being addressed in the evolving treatment landscape. In this article, we review the role of frontline ASCT in the management of patients with MM.
- Published
- 2021
7. Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost
- Author
-
Ayrton Bangolo, Samir Oza, Ronit Slotky, Aimee Chappell, David Siegel, Harsh Parmar, Noa Biran, David H. Vesole, and Pooja Phull
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
8. The Clinical Characteristics and Epidemiology of Extramedullary Multiple Myeloma over the Past Two Decades
- Author
-
Ayrton Bangolo, Pierre Fwelo, Chinmay Trivedi, Jennifer Hashem, Parul Jandir, Katamon Klaichart, Rua Abdelrahim, Ayodya R Perera, Manbir Singh, Rohini B Gurumoorthy, Apurva Tiwari, Sudha S Konakanchi, Nagihan Orhun, Adithya Polavarapu, Ritika Sharma, Ankit Sarkar, Anupama Gupta, Bob-Hallen E. Treisma, Thin Thiri Soe, Ashwin Penchala, Sheetal Penmetsa, Srikar Bathi, Padmavathi Muppalla, David Siegel, Noa Biran, Harsh Parmar, David H. Vesole, Simcha Weissman, and Pooja Phull
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
9. Effect of Daratumumab on Stem Cell Mobilization and Engraftment Kinetics Post Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
- Author
-
Samir Oza, Ronit Slotky, Pranay Vissa, Pooja Phull, Sukhdeep Kaur, Hyung C. Suh, Michele L. Donato, Scott D. Rowley, Noa Biran, David H. Vesole, David Siegel, and Harsh Parmar
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
10. Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma
- Author
-
Shaji Kumar, Morie A. Gertz, Emilie I. Anderson, Harsh Parmar, and Taxiarchis Kourelis
- Subjects
Male ,Disease ,CD16 ,Transplantation, Autologous ,Immune Reconstitution ,Immune system ,Tumor Microenvironment ,Humans ,Medicine ,Elotuzumab ,Autografts ,Receptor ,In Situ Hybridization, Fluorescence ,Multiple myeloma ,Lymphoid Neoplasia ,biology ,business.industry ,Hematology ,medicine.disease ,Immunology ,biology.protein ,Antibody ,Stem cell ,Multiple Myeloma ,business ,medicine.drug - Abstract
The immediate postautologous stem cell transplant (ASCT) period in multiple myeloma represents a unique opportunity for long-term disease control because many patients have eradicated most of their disease but also a challenge because it is characterized by the increase of immune subsets detrimental to tumor immunosurveillance. The impact of the tumor immune microenvironment (iTME) in post-ASCT outcomes is not known. In this study, we included 58 patients undergoing upfront ASCT and evaluated their cellular and humoral iTME with cytometry by time of flight (CyTOF) and luminex, respectively, at day +60 to 100 post-ASCT. We identified 2 cellular iTME patterns. Group 1 was enriched in T-cell subsets at the opposite ends of the spectrum of T-cell differentiation compared with the rest of the patients, that is, cells already terminally differentiated (immune senescent or exhausted) and naive T cells. This group had worse hematologic responses post-ASCT, inferior survival, and shorter time to hematologic progression independent of established risk factors. No differences in the humoral iTME were noted between the 2 groups. In addition, no differences in the cellular/humoral iTME were noted according to high-risk fluorescence in situ hybridization status, early or late relapse. Finally, males had higher levels of natural killer cells negative for CD16, a key receptor mediating antibody-dependent cell cytotoxicity, a major mechanism of antitumor efficacy by therapeutic antibodies such as elotuzumab. Our findings suggest that T-cell iTME dysfunction post-ASCT, some of which could be reversible (exhaustion), correlates with worse outcomes. These results could be used to guide rational selection of post-ASCT maintenance/consolidation approaches in these patients.
- Published
- 2021
11. Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation
- Author
-
Morie A. Gertz, Eli Muchtar, Wilson I. Gonsalves, Shaji Kumar, Harsh Parmar, Alissa Visram, Rahma Warsame, Robert C. Wolf, Taxiarchis Kourelis, Abdullah S. Al Saleh, Suzanne R. Hayman, David Dingli, Martha Q. Lacy, William J. Hogan, M. Hasib Sidiqi, Francis K. Buadi, Prashant Kapoor, Iuliana Vaxman, and Angela Dispenzieri
- Subjects
Transplantation ,medicine.medical_specialty ,Troponin T ,business.industry ,Amyloidosis ,Kidney dysfunction ,Urology ,Hematology ,medicine.disease ,Immunoglobulin light chain ,Autologous stem-cell transplantation ,medicine ,In patient ,business ,Value (mathematics) - Published
- 2020
12. Knowledge, attitude, and practice toward social media use in dental education
- Author
-
Manoj Mahadeo Ramugade, Surabhi Nabazza, Gulam Anwar Naviwala, Kishor Dattatray Sapkale, Harsh Parmar, and Sayed Abrar
- Subjects
Government ,Medical education ,knowledge ,business.industry ,media_common.quotation_subject ,social media ,Usability ,Mean age ,General Medicine ,Dental education ,practice ,Traditional education ,lcsh:RK1-715 ,dental education ,Perception ,attitude ,lcsh:Dentistry ,Educational content ,Social media ,Psychology ,business ,media_common - Abstract
Introduction: The use of social media has been a revolutionary way of communication, since the past decade. Considering its high level of usage among the younger individuals, social media may provide a unique method of learning for dental students. However, the perception of dental educators on the usage of social media and networking sites is unknown. Hence, this study was conducted to assess the knowledge, attitude, and practice of dental faculty and residents toward social media use in dental education. Materials and Methods: This cross-sectional study was conducted in Government Dental College and Hospital, Mumbai, from November 2019 to December 2019. The questionnaire was prepared and validated before conducting the study. All the faculty members and the residents of the college were included in the study. The questionnaire was based on three dimensions (knowledge, attitude, and practice) and assessed the views of participants on the social media usage. Results: A total of 65 participants were included in the study, where 32 were faculty members and 33 were residents. The mean age of the participants was 31.52 ± 6.589. Out of the total, 26 (40%) participants were male and 39 (60%) were female. The mean experience of the study participants was 4.71 ± 5.997. The responses were compared between residents and faculty and the responses were similar for most knowledge, attitude, and practice question. The residents were keener on looking forward to developing social media as a primary aid in dental education compared to the faculty (P = 0.029). Conclusion: Due to ease of use and widespread applicability, social media now has a great potential to deliver educational content. This study demonstrates the positive responses of the faculty towards social media usage and further enhances traditional education.
- Published
- 2020
13. Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients
- Author
-
Taxiarchis Kourelis, Suzanne R. Hayman, Nelson Leung, John A. Lust, Eli Muchtar, Harsh Parmar, Prashant Kapoor, Iuliana Vaxman, Angela Dispenzieri, Abdullah S. Al Saleh, Yi L. Hwa, David Dingli, Miriam Hobbs, Amie Fonder, Jennifer S. McDonald, Wilson I. Gonsalves, Martha Q. Lacy, John C. Lieske, Morie A. Gertz, Shaji Kumar, Robert A. Kyle, Alissa Visram, S. Vincent Rajkumar, Rahma Warsame, Mustaqeem A. Siddiqui, and Francis K. Buadi
- Subjects
Male ,medicine.medical_specialty ,Urology ,Urine ,030204 cardiovascular system & hematology ,lcsh:RC254-282 ,Article ,Urine collection device ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Diagnosis ,AL amyloidosis ,medicine ,Albuminuria ,Humans ,Immunoglobulin Light-chain Amyloidosis ,Signs and symptoms ,Aged ,Retrospective Studies ,Creatinine ,Proteinuria ,business.industry ,Retrospective cohort study ,Hematology ,Gold standard (test) ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Female ,medicine.symptom ,business ,Haematological diseases - Abstract
A 24-h urine protein collection (24hUP), the gold standard for measuring albuminuria in systemic AL amyloidosis, is cumbersome and inaccurate. We retrospectively reviewed 575 patients with systemic AL amyloidosis to assess the correlation between a urine albumin to creatinine ratio (uACR) and the 24hUP. The uACR correlated strongly with 24hUP at diagnosis (Pearson’s r = 0.87, 95% CI 0.83–0.90) and during the disease course (Pearson’s r = 0.88, 95% CI 0.86–0.90). A uACR ≥300 mg/g estimated a 24hUP ≥ 500 mg with a sensitivity of 92% and specificity of 97% (area under the receiver operating curve = 0.938, 95% CI 0.919–0.957). A uACR cutoff of 3600 mg/g best predicted a 24hUP > 5000 g (sensitivity 93%, specificity 94%), and renal stage at diagnosis was strongly concordant using either 24hUP or uACR as the proteinuria measure (k = 0.823, 95% CI 0.728–0.919). In patients with serial urine collections, a > 30% decrease in uACR predicted a > 30% decrease in 24hUP with a sensitivity of 94%. In conclusion, the uACR is a reliable and convenient method for ruling out proteinuria >500 mg per day, prognosticating renal outcomes, and assessing renal response to therapy. Further studies are needed to validate the uACR cutoffs proposed in this study.
- Published
- 2020
14. Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients
- Author
-
John A. Lust, Shaji Kumar, Eli Muchtar, Harsh Parmar, David L. Murray, Prashant Kapoor, Iuliana Vaxman, Morie A. Gertz, Rahma Warsame, Robert A. Kyle, Angela Dispenzieri, Mustaqeem A. Siddiqui, Martha Q. Lacy, Francis K. Buadi, Taxiarchis Kourelis, Suzanne R. Hayman, S. Vincent Rajkumar, Wilson I. Gonsalves, Alissa Visram, David Dingli, Abdullah S. Al Saleh, and Nelson Leung
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Disease Response ,Disease-free survival ,Myeloma ,Serum iga ,Gastroenterology ,Article ,Internal medicine ,medicine ,Humans ,Survival analysis ,Multiple myeloma ,Aged ,Monitoring, Physiologic ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,Hematology ,Disease monitoring ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Immunoglobulin A ,Response assessment ,Myeloma Proteins ,Oncology ,Serum protein electrophoresis ,Disease Progression ,Female ,Disease assessment ,business ,Multiple Myeloma - Abstract
Unlike IgG monoclonal proteins (MCPs), IgA MCP quantification is unreliable due to beta-migration of IgA MCPs on serum protein electrophoresis (SPEP). The utility of nephelometric quantitative IgA (qIgA) to monitor IgA multiple myeloma (MM) is unclear. We retrospectively studied disease response kinetics using qIgA versus MCPs by SPEP, and developed and validated novel qIgA disease assessment criteria in 491 IgA MM patients. The SPEP MCP nadir occurred a median of 41 (IQR 0–102) days before the qIgA. The median time to achieve a partial response (PR) was shorter using standard IMWG versus qIgA response criteria (32 vs 58 days, p
- Published
- 2020
15. Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients
- Author
-
Morie A. Gertz, Ronald S. Go, Shaji Kumar, Francis K. Buadi, Robert A. Kyle, Harsh Parmar, Martha Q. Lacy, Abdullah S. Al Saleh, David Dingli, Alissa Visram, Eli Muchtar, Angela Dispenzieri, S. Vincent Rajkumar, Wilson I. Gonsalves, Rahma Warsame, Taxiarchis Kourelis, Nelson Leung, and Prashant Kapoor
- Subjects
Oncology ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Plasma Cells ,Tumor burden ,Newly diagnosed ,Plasma cell ,Independent predictor ,Article ,03 medical and health sciences ,0302 clinical medicine ,Bone Marrow ,Internal medicine ,medicine ,Humans ,Multiple myeloma ,Aged ,Retrospective Studies ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Bone marrow ,business ,Multiple Myeloma ,030215 immunology - Abstract
In the current era, the impact of bone marrow plasma-cell percentage (BMPC%) at diagnosis of multiple myeloma (MM) is not well described. We evaluated the prognostic impact of BMPC% ≥ 60% versus < 60% in 1426 newly diagnosed MM patients. Median progression-free and overall survival were shorter for patients with BMPC% ≥ 60%, even in a multivariate analysis that included known prognostic factors for MM. BACKGROUND: Previous reports have suggested that a higher bone marrow plasma-cell percentage (BMPC%) is associated with worse outcomes. However, it is unknown whether BMPC% is an independent predictor because genetic information was not available at that time. Currently the impact of BMPC% at diagnosis of multiple myeloma (MM) is not well described. PATIENTS AND METHODS: We evaluated the prognostic impact of BMPC% ≥ 60% versus < 60% in 1426 newly diagnosed MM patients. All patients had an estimation of their BMPC% at diagnosis, and the highest percentage was used. Progression-free survival (PFS) and overall survival (OS) analyses were performed by the Kaplan-Meier method. Univariate and multivariate analyses for PFS and OS using the Cox proportional hazards model were performed for age, Revised International Staging System (R-ISS) score, creatinine level, and BMPC%. RESULTS: BMPC% ≥ 60% was found in 562 patients (39%), and the median PFS was shorter for these patients compared to BMPC% < 60% (22.6 vs. 32.1 months; P < .0001). Also, for OS, the median was shorter for the higher BMPC% group (53.4 vs. 75.4 months; P < .0001). On the multivariate analysis for PFS, age ≥ 65 years (hazard ratio [HR], 1.46; P < .0001), R-ISS (1-2 vs. 3) (HR, 0.49; P < .0001), and BMPC% ≥ 60% (HR, 1.23; P = .015) were predictive. On the multivariate analysis for OS, age ≥ 65 years (HR, 2.23; P < .001), R-ISS (1-2 vs. 3) (HR, 0.41; P < .0001), and BMPC% ≥ 60% (HR, 1.24; P = .02) were also predictive. CONCLUSION: BMPC% ≥ 60% at diagnosis is predictive for PFS and OS, even in a multivariate analysis that included known prognostic factors for MM.
- Published
- 2020
16. A Novel Design for Voice-Enabled Home Automation and Personalized Recommendation System
- Author
-
Narendra Shekokar, Pranjali Thakre, and Harsh Parmar
- Subjects
Raspberry pi ,Mode (computer interface) ,Multimedia ,Home automation ,business.industry ,Computer science ,Control (management) ,ComputerApplications_COMPUTERSINOTHERSYSTEMS ,Recommender system ,business ,computer.software_genre ,computer - Abstract
Technology has completely changed the way we interact with the machines around us. Today, with everyone having access to devices like smartphones, voice has now become the primary and the most preferred mode of communication. We can also use this mode of communication to control various devices and applications at our home—a voice-controlled standalone device. We can develop a device with the help of Raspberry Pi and Relays to automate some of the manual day-to-day activities like switching on/off electrical appliances at home. Further, with the help of content-based recommendation, we can enable a device to suggest recommendations based on that individual’s past activities. Hence, this device can serve as a voice-controlled personalized home assistant.
- Published
- 2020
17. Inferior Outcomes of Patients with Quad and Penta-Refractory Multiple Myeloma (MM) Compared to Those of Patients Who Have Been Quad and Penta Exposed
- Author
-
Sarvarinder K Gill, Rashmi Unawane, Shuqi Wang, Adolfo Aleman, Michelle Serna, Fideliza Perez-Manon, Gina Rivieccio, David S. Siegel, David H. Vesole, Harsh Parmar, Jaeil Ahn, and Noa Biran
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Abstract
Background: Despite significant advancements in MM therapies, patients with quad-refractoriness (refractory to proteasome inhibitors: bortezomib and carfilzomib, and immunomodulatory drugs: lenalidomide and pomalidomide) and penta-refractoriness (additional refractoriness to CD-38+ monoclonal antibody daratumumab) have a poor prognosis in terms of short progression-free survival (PFS) and overall survival (OS). This is a retrospective, single institutional study comparing the outcomes of patients with quad and penta-refractory MM to patients who were quad and penta-exposed, but not refractory. Methods: Consecutive patients from the John Theurer Cancer Center at Hackensack Meridian School of Medicine who were quad and penta-exposed and/or refractory between the dates of 1/1/2015 and 3/1/2021 were identified. Quad-exposed was defined as having had prior exposure to bortezomib, carfilzomib, lenalidomide and pomalidomide. Penta-exposed was defined as having prior exposure to bortezomib, carfilzomib, lenalidomide and pomalidomide and daratumumab. Penta or quad refractory was defined as having stable disease (as best response) or progressive disease while on all of the above drugs, per International Myeloma Working Group (IMWG) definition of refractory. Patients were excluded if they had missing data or if they did not meet the above definitions. Baseline characteristics, high-risk status, ISS, treatment history, treatment response, drugs at first relapse and survival outcomes were obtained retrospectively from the electronic medical record and entered into database. High-risk cytogenetics were defined as the presence of t(4;14), t(14;16) or del 17p; 1q21 gain or amplification; 1p del; t(6;14); t(14;20). Baseline patients' characteristics were summarized descriptively by quad and penta-exposed groups. PFS and OS were estimated using the Kaplan-Meier method. Univariate and multivariable adjusted Cox proportional hazard regression models examined factors affecting OS. Results: A total of 162 patients met the inclusion criteria: 18/162 (11%) were quad or penta-exposed, 32/162 (20%) were quad-refractory, and 112/162 (69%) were penta-refractory. Median age was 62 (55-69), IgG subtype (59%), and 62/162 (38.5%) had high-risk cytogenetics. The median number of lines prior was 6 (range 4-8) among all patients, and 7 (range 5-9) in the penta-refractory group. 133/162 (82.1%) had prior autologous-stem cell transplant (ASCT). Extramedullary disease was present in 40/162 (25.2%). Plasma cell leukemia was present in 14/162 (8.8%). For those who were penta-refractory, the median time from quad to penta-refractory status was 10.2 months (95% confidence interval (CI), 3.57-16.57). See Table 1. Figure 1 shows PFS and OS from the time of becoming quad or penta-exposed or refractory (T0 ). The median PFS after T0 was 11.86 months (95% CI, 6.5-26.6) for combined quad and penta-exposed, compared to 3.88 months (95% CI, 2.99-5.17) for quad and penta-refractory patients. With a median follow-up of 5.14 months (Range, 0-52.4), the median OS for all patients was 7.43 months (95% CI, 5.8- 12.94). (Figure 1A). With a median follow-up time of 4.45 months (Range, 0-52.38), the median OS for patients who were quad or penta-refractory was 5.97 months [95% CI. 4.44-8.23], compared to OS not reached (NR) for quad or penta-exposed, with a median follow-up of 11.86 months. (Figure 1B). At least one subsequent treatment regimen was employed after T0 in 85% of the patients. (Figure 1C). Multivariable adjusted analysis (Table 2) revealed that patients ≥62 had inferior OS compared to those < 62 (p -value=0.046). Furthermore, patients who had ≤10 months between becoming quad- and penta-refractory had inferior OS compared to patients with >10 months (p=0.031). OS was not significantly affected by high risk versus standard cytogenetics or drugs used at first relapse. Conclusion: MM patients with quad and penta-refractory disease have significantly worse outcomes compared to patients with quad and penta-exposed MM: older age (> 62 years) and a short interval (< 10 months) between becoming quad and penta-refractory confer an adverse prognosis. Prospective studies are required to confirm these findings. Penta and quad-refractory multiple myeloma continues to represent a vulnerable population with an unmet need for therapeutic approaches. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
- Published
- 2021
18. Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation
- Author
-
Rahma Warsame, Angela Dispenzieri, Taxiarchis Kourelis, Morie A. Gertz, Prashant Kapoor, Harsh Parmar, Iuliana Vaxman, Abdullah S. Al Saleh, Wilson I. Gonsalves, Martha Q. Lacy, William J. Hogan, David Dingli, Francis K. Buadi, Shaji Kumar, M. Hasib Sidiqi, Alissa Visram, Eli Muchtar, and Robert C. Wolf
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Cell Biology ,Hematology ,Biochemistry ,Clinical trial ,Autologous stem-cell transplantation ,Family medicine ,Medicine ,In patient ,business ,Bristol-Myers ,Left ventricular wall - Abstract
Introduction: Cardiac involvement is one of the main predictors for survival in patients with light chain (AL) amyloidosis. Biomarkers such as Troponin T and N-terminal pro b-type natriuretic peptide (NT-proBNP) are used routinely for detecting cardiac involvement. In addition echocardiogram (ECHO) is used to determine septal and left ventricular wall thickness and strain. Most patients with AL present with preserved ejection fraction (EF) however, the outcomes of AL patients undergoing autologous stem cell transplantation (ASCT) with decreased EF are not very well described. Methods: We retrospectively reviewed patients who had a diagnosis of AL amyloidosis and received ASCT between March 1996 and September 2017. All patients had an ECHO done before ASCT and the EF was documented. In our practice, the threshold for performing ASCT is an EF >40%. We evaluated the outcomes of patients who had an EF 65 vs. ≤65 years, Mayo 2012 stage 3/4 vs. 1/2, bone marrow plasma cell percentage (BMPC) ≥ 10% vs. 2 vs. ≤2, melphalan conditioning 200mg/m2 vs. 140 mg/m2 ,ASCT year >2010 vs. ≤2010, and EF Results: We identified 716 patients and 69 (10%) had an EF Overall, PFS and OS were significantly shorter in patients with EF 2010 vs. ≤2010 (HR: 0.7, P=0.01), and EF 65 vs. ≤65 years (HR:1.4, P=0.04), Mayo 2012 stage 3/4 vs. 1/2 (HR: 1.96, P2010 vs. ≤2010 (HR: 0.5, P Conclusion: Having an EF Disclosures Sidiqi: Janssen: Honoraria; Amgen: Honoraria; Celgene: Honoraria, Other: Travel grant. Dingli:Alexion: Consultancy; Apellis: Consultancy; Sanofi-Genzyme: Consultancy; Millenium: Consultancy; Bristol Myers Squibb: Research Funding; Karyopharm Therapeutics: Research Funding; Janssen: Consultancy; Rigel: Consultancy. Kapoor:Janssen: Research Funding; GlaxoSmithKline: Research Funding; Cellectar: Consultancy; Sanofi: Consultancy, Research Funding; Celgene: Honoraria; Takeda: Honoraria, Research Funding; Amgen: Research Funding. Dispenzieri:Janssen: Research Funding; Pfizer: Research Funding; Alnylam: Research Funding; Intellia: Research Funding; Takeda: Research Funding; Celgene: Research Funding. Kumar:AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Merck: Consultancy, Research Funding; Adaptive Biotechnologies: Consultancy; Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Dr. Reddy's Laboratories: Honoraria; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; Kite Pharma: Consultancy, Research Funding; Novartis: Research Funding; Sanofi: Research Funding; MedImmune: Research Funding; Karyopharm: Consultancy; BMS: Consultancy, Research Funding; Tenebio: Other, Research Funding; Genecentrix: Consultancy; Cellectar: Other; Carsgen: Other, Research Funding. Gertz:Spectrum: Other: personal fee, Research Funding; Janssen: Other: personal fee; Sanofi: Other; Research to Practice: Other; Celgene: Other; Medscape: Other: personal fee, Speakers Bureau; Proclara: Other; DAVA oncology: Speakers Bureau; Alnylam: Other: personal fee; Johnson and Johnson: Speakers Bureau; Physicians Education Resource: Other: personal fee; Teva: Speakers Bureau; Ionis/Akcea: Other: personal fee; Amgen: Other: personal fee; Springer Publishing: Patents & Royalties; Aurora Bio: Other; Appellis: Other: personal fee; Abbvie: Other; Annexon: Other: personal fee; Prothena: Other: personal fee.
- Published
- 2020
19. Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis
- Author
-
Martha Q. Lacy, Ronald S. Go, Harsh Parmar, S. Vincent Rajkumar, Eli Muchtar, Shaji Kumar, Wilson I. Gonsalves, Rahma Warsame, Robert A. Kyle, Abdullah S. Al Saleh, Angela Dispenzieri, Prashant Kapoor, Francis K. Buadi, Morie A. Gertz, Alissa Visram, David Dingli, Nelson Leung, and Taxiarchis Kourelis
- Subjects
Pediatrics ,medicine.medical_specialty ,business.industry ,Immunology ,Retrospective analysis ,Medicine ,Cell Biology ,Hematology ,Newly diagnosed ,business ,medicine.disease ,Biochemistry ,Multiple myeloma - Abstract
Introduction: In general, the use of an immunomodulator (IMiD), proteasome inhibitors (PI) and dexamethasone (dex) for the treatment of MM is associated with better outcomes. The management of elderly patients with multiple myeloma (MM) is challenging due to difficulty in managing their co-morbidities and inability to tolerate treatment side effects. We evaluated therapies and outcomes of elderly patients with newly diagnosed MM. Methods: This is a retrospective study of patients with MM who were >75 years old treated at the Mayo Clinic, Rochester from January 2004 to January 2018. We included patients who were treated on clinical trials as well as off-trials. Patients were classified as receiving treatment with IMiD+PI+dex, alkylator+PI+steroid, IMiD+dex, PI+dex, alkylator+IMid+steroid, and other (alkylator with steroid or steroid only). Treatment response was documented as well as the progression-free (PFS), defined as the time from therapy initiation to disease relapse or death from any cause and overall survival (OS), defined as the time from start of treatment to death from any cause. A multivariate analysis for factors affecting OS was done including the following variables: being on a triplet combination (alkylator+PI+steroid, IMid+PI+dex, or alkylator +IMiD+steroid), revised international staging system (R-ISS)(stage 3 vs. 1-2), bone marrow plasma cell percentage (BMPC%)(>60% vs. ≤60%), and receiving treatment during or after 2010 vs. before 2010. Analysis was done for patients treated off-trials, as well as, including trial patients. Results: We identified 394 patients with MM who were >75 years old and 246 (62%) were male. For non-trial patients (n=350), IMiD+dex (32%) was the most commonly used regimen followed by alkylator with steroid or steroid only (20%), alkylator+PI+steroid (18%), and IMid+PI+dex (13%). The remaining patients were treated with PI+dex (12%) and alkylator +IMiD+steroid (5%). Forty-four patients (11%) were treated in clinical trials with alkylator+IMid+steroid (47%), IMiD+dex (25%), IMiD+PI+dex (14%), and alkylator+PI+steroid (14%). The median follow up was 45.9 months with an interquartile range of 28.2 to 75.6 months. Overall, achieving very good partial response or complete response was more likely in patients who were treated with an IMid+PI+dex (58%) or alkylator+PI+steroid (47%), compared to in other therapies (5-30%)(P Conclusion: In MM patients >75 years old, being able to receive triplet therapy is associated with better survival. This study provides better understanding of the natural history of MM outside of trials in the elderly age group. Disclosures Dispenzieri: Celgene: Research Funding; Alnylam: Research Funding; Pfizer: Research Funding; Intellia: Research Funding; Takeda: Research Funding; Janssen: Research Funding. Dingli:Bristol Myers Squibb: Research Funding; Alexion: Consultancy; Millenium: Consultancy; Rigel: Consultancy; Sanofi-Genzyme: Consultancy; Apellis: Consultancy; Janssen: Consultancy; Karyopharm Therapeutics: Research Funding. Kapoor:GlaxoSmithKline: Research Funding; Amgen: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Consultancy, Research Funding; Janssen: Research Funding; Cellectar: Consultancy; Celgene: Honoraria. Gertz:Spectrum: Other: personal fee, Research Funding; Janssen: Other: personal fee; Prothena: Other: personal fee; Alnylam: Other: personal fee; Ionis/Akcea: Other: personal fee; Springer Publishing: Patents & Royalties; Proclara: Other; DAVA oncology: Speakers Bureau; Johnson and Johnson: Speakers Bureau; Teva: Speakers Bureau; Sanofi: Other; Research to Practice: Other; Celgene: Other; Abbvie: Other; Aurora Bio: Other; Physicians Education Resource: Other: personal fee; Medscape: Other: personal fee, Speakers Bureau; Amgen: Other: personal fee; Appellis: Other: personal fee; Annexon: Other: personal fee. Kumar:Carsgen: Other, Research Funding; Tenebio: Other, Research Funding; BMS: Consultancy, Research Funding; Karyopharm: Consultancy; MedImmune: Research Funding; Sanofi: Research Funding; Novartis: Research Funding; Kite Pharma: Consultancy, Research Funding; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Adaptive Biotechnologies: Consultancy; Merck: Consultancy, Research Funding; Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Dr. Reddy's Laboratories: Honoraria; Cellectar: Other; Genecentrix: Consultancy.
- Published
- 2020
20. Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis
- Author
-
Harsh Parmar, Shaji Kumar, David Dingli, Morie A. Gertz, Prashant Kapoor, Iuliana Vaxman, Eli Muchtar, Abdullah S. Al Saleh, Martha Q. Lacy, M. Hasib Sidiqi, Wilson I. Gonsalves, Taxiarchis Kourelis, Rahma Warsame, Robert C. Wolf, William J. Hogan, Angela Dispenzieri, and Francis K. Buadi
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Disease progression ,Monoclonal Spike ,Cell Biology ,Hematology ,Biochemistry ,Clinical trial ,Autologous stem-cell transplantation ,Serum free ,Family medicine ,Induction therapy ,medicine ,In patient ,business ,Bristol-Myers - Abstract
Introduction: The bone marrow plasma cell (BMPC) clone burden is typically low in light chain (AL) amyloidosis and some patients do not have a detectable serum monoclonal spike (M-spike). Increased BMPC% and serum free light chain (FLC) are associated with poorer outcomes. However, the outcomes of patients with AL amyloidosis based on the presence or an absence of a measurable serum M-spike before autologous stem cell transplantation (ASCT) has not been explored. Methods: This was a retrospective review of patients who had a diagnosis of AL amyloidosis and received ASCT between March 1996 and September 2017. The serum M-spike was recorded before ASCT and patients were divided according to the presence or absence of a measurable serum M-spike. Progression-free survival (PFS) was defined as time from ASCT to disease progression, relapse or death of any cause. Overall survival (OS) was calculated from time of ASCT to death of any cause. Univariate and multivariate analysis for PFS and OS were done using the following variables: age>65 vs. ≤65 years, Mayo 2012 stage 3/4 vs. 1/2, BMPC ≥ 10% vs. 2 vs. ≤2, melphalan conditioning 200mg/m2 vs. 140 mg/m2 ,ASCT year >2010 vs. ≤2010, and presence vs. absence of a measurable serum M-spike. Results: Seven-hundred and sixteen patients were identified and 521 (73%) had a measurable serum M-spike. Patients who had a measurable serum M-spike were more likely to have BMPC≥ 10% than patients without a measurable serum M-spike (46% vs. 34%, P=0.002) and they were more likely to have a difference in FLC ≥18 mg/dl (47% vs. 29%, P=0.0001). Overall, PFS and OS were significantly shorter in patients who had a measurable serum M-spike compared to patients without a measurable serum M-spike (Figure 1 A,B). The shorter survival was irrespective of the administration of induction therapy before ASCT. We also evaluated the difference in survival in patients with Mayo 2012 stage 3/4 based on the presence or absence of a measurable serum M-spike. The PFS and OS were also significantly different in these patients (Figure 1 C,D). Predictors for PFS included Mayo 2012 stage 3/4 vs. 1/2 (hazard ratio (HR): 1.5, P=0.003), BMPC ≥ 10% vs. 2010 vs. ≤2010 (HR: 0.8, P=0.03), and the presence vs. absence of a measurable serum M-spike (HR: 1.82, P2010 vs. ≤2010 (HR: 0.6, P=0.002), and the presence vs. absence of a measurable serum M-spike (HR:1.9, P=0.003) were predictive. Conclusion: The presence of a measurable serum M-spike before ASCT is a negative independent predictor for PFS and OS in AL amyloidosis. Figure 1 Disclosures Sidiqi: Amgen: Honoraria; Celgene: Honoraria, Other: Travel grant; Janssen: Honoraria. Dingli:Karyopharm Therapeutics: Research Funding; Apellis: Consultancy; Alexion: Consultancy; Janssen: Consultancy; Bristol Myers Squibb: Research Funding; Rigel: Consultancy; Millenium: Consultancy; Sanofi-Genzyme: Consultancy. Kapoor:Amgen: Research Funding; Celgene: Honoraria; Cellectar: Consultancy; Janssen: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Consultancy, Research Funding; GlaxoSmithKline: Research Funding. Dispenzieri:Intellia: Research Funding; Alnylam: Research Funding; Pfizer: Research Funding; Takeda: Research Funding; Celgene: Research Funding; Janssen: Research Funding. Kumar:Celgene/BMS: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Janssen Oncology: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; AbbVie: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Takeda: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Tenebio: Other, Research Funding; Genecentrix: Consultancy; MedImmune: Research Funding; Cellectar: Other; Dr. Reddy's Laboratories: Honoraria; Merck: Consultancy, Research Funding; Amgen: Consultancy, Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments, Research Funding; Novartis: Research Funding; Adaptive Biotechnologies: Consultancy; Kite Pharma: Consultancy, Research Funding; Oncopeptides: Consultancy, Other: Independent Review Committee; IRC member; Karyopharm: Consultancy; BMS: Consultancy, Research Funding; Carsgen: Other, Research Funding; Genentech/Roche: Other: Research funding for clinical trials to the institution, Consulting/Advisory Board participation with no personal payments; Sanofi: Research Funding. Gertz:Proclara: Other; Abbvie: Other; DAVA oncology: Speakers Bureau; Aurora Bio: Other; Prothena: Other: personal fee; Teva: Speakers Bureau; Physicians Education Resource: Other: personal fee; Annexon: Other: personal fee; Ionis/Akcea: Other: personal fee; Sanofi: Other; Appellis: Other: personal fee; Amgen: Other: personal fee; Janssen: Other: personal fee; Spectrum: Other: personal fee, Research Funding; Medscape: Other: personal fee, Speakers Bureau; Research to Practice: Other; Alnylam: Other: personal fee; Johnson and Johnson: Speakers Bureau; Springer Publishing: Patents & Royalties; Celgene: Other.
- Published
- 2020
21. Ageism in the t(11;14) Subtype of Multiple Myeloma
- Author
-
Wilson I. Gonsalves and Harsh Parmar
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Extramural ,MEDLINE ,Hematology ,General Medicine ,medicine.disease ,Ageism ,Surveys and Questionnaires ,Internal medicine ,Humans ,Medicine ,Multiple Myeloma ,business ,Multiple myeloma - Published
- 2020
22. Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma
- Author
-
Rahma Warsame, Shaji Kumar, Harsh Parmar, Alissa Visram, Morie A. Gertz, Abdullah S. Al Saleh, Wilson I. Gonsalves, Angela Dispenzieri, Suzanne R. Hayman, Taxiarchis Kourelis, Francis K. Buadi, Martha Q. Lacy, Eli Muchtar, David Dingli, and Prashant Kapoor
- Subjects
Immunofixation ,medicine.medical_specialty ,Immunoglobulin light chain ,Transplantation, Autologous ,Gastroenterology ,Disease-Free Survival ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,In patient ,Survival analysis ,Multiple myeloma ,Retrospective Studies ,Transplantation ,biology ,business.industry ,Hematopoietic Stem Cell Transplantation ,Cell Biology ,Hematology ,Prognosis ,medicine.disease ,Cohort ,biology.protein ,Molecular Medicine ,Monoclonal protein ,Multiple Myeloma ,business - Abstract
Patients who undergo autologous stem cell transplantation (ASCT) for multiple myeloma (MM) are routinely assessed at day +100 using serum and urine protein electrophoresis/immunofixation and the serum free light chain (sFLC) assay. We evaluated whether an increase in M-spike or FLC from immediately before ASCT to day +100 post-ASCT has any prognostic impact. We retrospectively reviewed 1218 patients with MM at the Mayo Clinic who underwent their first ASCT between 2000 and 2016. We stratified patients into those with a rise in M-spike by at least 0.1 g/dL from immediately before ASCT to day +100 post-ASCT (M-spike cohort 1) and those who did not (M-spike cohort 2). We also stratified patients into those with a rise in the involved FLC by at least 5 mg/dL (FLC cohort 1) and those who did not (FLC cohort 2). Survival analysis for progression-free survival (PFS) and overall survival (OS) was performed using the Kaplan-Meier method. A rise in M-spike by at least 0.1 g/dL from pre-ASCT to day +100 was seen in 53 patients (4.3%). The median PFS and OS were found to be significantly shorter in M-spike cohort 1 compared with their counterparts (median PFS, 10 months versus 26 months [P < .0001]; median OS, 35 months versus 79 months [P < .0001]). An increase in involved FLC by at least 5 mg/dL was observed in 25 patients (2.3%). Similarly, the median PFS and OS were found to be inferior in FLC cohort 1 compared with FLC cohort 2 (median PFS, 4 months versus 28 months [P < .0001]; median OS, 11 months versus 82 months [P < .0001]). An increase of M-spike by at least 0.1 g/dL and an increase in involved FLC by at least 5 mg/dL from pre-ASCT to day +100 increases the likelihood of an early relapse after ASCT, and these patients may benefit from closer surveillance after day +100.
- Published
- 2021
23. Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis
- Author
-
Eli Muchtar, Harsh Parmar, Morie A. Gertz, Alissa Visram, Abdullah S. Al Saleh, Nelson Leung, Francis K. Buadi, Jennifer S. McDonald, Iuliana Vaxman, and Angela Dispenzieri
- Subjects
Cancer Research ,medicine.medical_specialty ,Creatinine ,Proteinuria ,business.industry ,Amyloidosis ,Urology ,Albumin ,Gold standard (test) ,medicine.disease ,Immunoglobulin light chain ,Spot urine ,chemistry.chemical_compound ,Oncology ,chemistry ,Medicine ,medicine.symptom ,business - Abstract
8549 Background: Proteinuria evaluation is essential for diagnosing and monitoring of renal involvement in light chain (AL) amyloidosis. A 24 hour protein collection (24h UP) is the gold standard for proteinuria assessment however it is cumbersome and can be inaccurate. A spot urine albumin to creatinine ratio (uACR) has been proposed as a convenient method to estimate 24hUP. We aimed to validate the correlation between uACR and 24hUP in a large cohort of patients. Methods: We retrospectively studied systemic AL amyloidosis patients evaluated between 2010 and 2019 at Mayo Clinic, with a uACR and 24hUP collected less than 7 days apart. Linear regression analysis was used to construct a prediction model for 24hUP with uACR as the primary predictor. Possible confounders (age, gender, body mass index, morning versus afternoon spot urine collection, estimated glomerular filtration rate) for the primary relationship between uACR and 24h UP were evaluated in the model. We used receiver operating characteristic (ROC) analysis to identify the best uACR cutoff to predict significant proteinuria (defined as a 24hUP > 500mg). Results: We included 665 patients, with a median age of 66 years (IQR 59-72). The spot urine was collected in the morning (before 1200 hours) in 382 (57%) patients, and in the afternoon in 283 (43%) patients. The median 24hUP was 321 (IQR 129-2512.5) mg, median uACR was 107 (IQR 13.5-1845) mg/g, and median serum creatinine was 1.2 (IQR 1-1.8) mg/dL. The uACR correlated well with 24h UP (Pearson’s r= 0.83, 95% CI 0.80-0.85). Linear regression showed that E (24h UPi) = 362 + 1.05(uACRi), and this model was statistically and clinically significant (p < 0.001 and R2 of 0.68, respectively). Age, gender, body mass index, eGFR, and time of day of spot urine collection did not confound the primary relationship between uACR and 24hUP, and no collinearity was observed. A uACR cutoff of > 280 mg/g was the best predictor of a 24hUP > 500 mg (area under the ROC curve 0.98, sensitivity 92%, specificity 97%). For simplicity, we assessed the predictive value of uACR > 300 mg/g for 24h UP > 500 mg. Among patients with 24huACR > 300 mg/g 264 (96%) had a 24hUP > 500 mg, and 31 (7%) of patients with uACR < 300 mg/g had a 24h UP > 500 mg (p < 0.001). Conclusions: In systemic AL amyloid patients, we showed that uACR on a random urine sample correlated well with 24h UP, and can be used to estimate proteinuria with a linear regression model. Based on these findings, and the convenience of uACR testing for patients, we propose that uACR should be used to monitor renal response to AL amyloidosis therapy.
- Published
- 2020
24. Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels
- Author
-
Angela Dispenzieri, S. Vincent Rajkumar, Shaji Kumar, Wilson I. Gonsalves, Abdullah S. Al Saleh, Francis K. Buadi, Morie A. Gertz, Rahma Warsame, Suzanne R. Hayman, Eli Muchtar, Mustaqeem A. Siddiqui, Taxiarchis Kourelis, Harsh Parmar, Alissa Visram, Martha Q. Lacy, David L. Murray, John A. Lust, Prashant Kapoor, and David Dingli
- Subjects
Cancer Research ,Oncology ,medicine.diagnostic_test ,IgA.monoclonal ,business.industry ,Serum protein electrophoresis ,Immunology ,medicine ,Serum iga ,Beta (finance) ,business ,medicine.disease ,Multiple myeloma - Abstract
e20515 Background: IgA monoclonal proteins (MCPs), unlike IgG MCPs, often migrate in the beta region on serum protein electrophoresis (SPEP) which can lead to underestimation of their size due to the co-migration with physiologic proteins. In IgA multiple myeloma (MM), the utility of quantitative IgA levels in assessing disease response in comparison to SPEP is not well studied. Methods: We retrospectively analyzed 304 IgA MM patients, diagnosed between 2004 and 2018, with available serial MCP and quantitative IgA levels. Kaplan Meier analysis was used to estimate the median progression free survival (mPFS) using the IMWG criteria and our study definition of IgA progression (2 consecutive IgA values that are > 25% above the nadir IgA value and above upper limit of normal (ULN) of 356 mg/dL, and a detectable IgA MCP on serum immunofixation). The mPFS was defined as the time from treatment initiation until disease progression or death. Results: IgA MCP migrated in the beta region in 134 (44%) patients, and in the gamma region in 150 (56%) patients. At diagnosis the median MCP was 3 (IQR 1.9-4) g/dL and the median IgA was 3240 (IQR 2008-4420) mg/dL. The median time from treatment initiation to MCP nadir was 80 (IQR 42-144) days and median time to IgA nadir was 154 (IQR 90-238) days. At MCP nadir 40% of patients had an IgA above the ULN. All complete responders (n = 104) had normal IgA levels, with a median IgA of 54 (IQR 27-88) g/dL. A ≥90% decrease in IgA between treatment initiation and IgA nadir, compared to a < 90% decrease, was associated with a longer mPFS (34 vs. 20 months, p = 0.006) and overall survival (97 vs. 33 months, p = 0.003). Patients with serial MCP and IgA levels available prior to progression (n = 195) were used to compare the mPFS using the IMWG and IgA progression criteria. The mPFS using the IgA criteria was 32 (95% CI 29-39) months, versus 39 (95% CI 33-45) months using IMWG criteria. Overall, 92 (47%) patients progressed by both IMWG and IgA criteria. At the time of progression using the IgA criteria compared to at IMWG progression, the median hemoglobin was higher (13.3 vs. 11.6 g/dL, respectively, p < 0.001) and fewer patients had new symptomatic bone lesions (2% vs. 33%, respectively, p < 0.001). Conclusions: In IgA MM patients, monitoring quantitative IgA levels predicts disease response and allows for earlier detection of disease progression, prior to the development of end organ damage.
- Published
- 2020
25. Implications of a Rising Serum Monoclonal Protein and Free Light Chains Post Autologous Stem Cell Transplant in Patients with Multiple Myeloma
- Author
-
Eli Muchtar, Harsh Parmar, Taxiarchis Kourelis, Shaji Kumar, Francis K. Buadi, Prashant Kapoor, Morie A. Gertz, Angela Dispenzieri, Alissa Visram, Abdullah S. Al Saleh, Martha Q. Lacy, Wilson I. Gonsalves, Rahma Warsame, Suzanne R. Hayman, and David Dingli
- Subjects
Oncology ,Transplantation ,medicine.medical_specialty ,business.industry ,Hematology ,Immunoglobulin light chain ,medicine.disease ,Internal medicine ,Cohort ,medicine ,In patient ,Progression-free survival ,Stem cell ,Monoclonal protein ,business ,Survival analysis ,Multiple myeloma - Abstract
Background Patients(pts) who undergo autologous stem cell transplant (ASCT) for multiple myeloma (MM) are routinely assessed at Day-100 using serum monoclonal protein (M-spike), free light chains(FLC), and urine studies. Limited data are available to assess the prognostic value of an increasing M-spike or FLC from immediately before ASCT to Day-100 post-ASCT. We evaluated this in our cohort of patients. Methods We retrospectively reviewed 1070 pts with MM at Mayo Clinic, Rochester, who had their first ASCT between 2000 and 2016. We stratified pts according to a rise in M-spike by at least >0.1g/dl from immediately before ASCT to Day-100 post-ASCT (cohort 1) compared to those who did not (cohort 2). We also stratified pts according to a rise in involved FLC by at least >5mg/dl (cohort 3) compared to those who did not (cohort 4). Survival analysis for progression free survival (PFS) and overall survival (OS) was performed using the Kaplan Meier method. Results 46 pts were found to have a rise in M-spike by at least >0.1g/dl between pre-ASCT and Day-100 (cohort 1) and 825 pts were found to have a declining or 5mg/dl (cohort 3) and 1045 pts were found to have a decrease or a Conclusions An increase of M-spike by at least >0.1 g/dl and involved FLC by at least >5mg/dl from pre-ASCT to Day-100 is predictive of inferior PFS and OS in pts with MM. These patients would benefit from closer surveillance post Day-100.
- Published
- 2020
26. Emotional Intelligence and its Correlation with Academic Performance of Dental Undergraduates
- Author
-
Ketki Kulkarni, Dhirajkumar Mane, Shailaja Patil, Pronob Sanyal, and Harsh Parmar
- Subjects
Correlation ,Emotional intelligence ,Public Health, Environmental and Occupational Health ,Psychology ,Developmental psychology - Published
- 2019
27. ATPS-71EFFICACY OF TEMOZOLOMIDE IN AN ADULT WITH MEDULLOBLASTOMA, REVIEW OF SERIES OF TWO PATIENTS
- Author
-
Sumul Raval, Harsh Parmar, Ruchi Raval, and Lajja Majmundar
- Subjects
Oncology ,Medulloblastoma ,Cancer Research ,medicine.medical_specialty ,Vincristine ,Chemotherapy ,Temozolomide ,Adult Medulloblastoma ,business.industry ,medicine.medical_treatment ,medicine.disease ,Carboplatin ,Surgery ,Radiation therapy ,stomatognathic diseases ,chemistry.chemical_compound ,Regimen ,chemistry ,Internal medicine ,medicine ,Neurology (clinical) ,business ,Abstracts from the 20th Annual Scientific Meeting of the Society for Neuro-Oncology ,medicine.drug - Abstract
Medulloblastoma is a malignant CNS tumor which is essentially a disease of childhood. It occurs infrequently in adults accounting for less than 1% of all intracranial tumors in adults. Due to the relative infrequency in adults, the clinical characteristics of this disease are not well defined in adults in comparison to children, and optimal treatment is not well established. Complete tumor resection with CSI radiation is the standard of care for treatment of adult medulloblastoma. In contrast to childhood medulloblastoma, the role of chemotherapy in adult population is undetermined. A number of chemotherapy agents in treatment of pediatric medulloblastoma have been evaluated and used including vincristine, CCNU, cisplatin, carboplatin, and cyclophosphamide. We report a case series of two patients diagnosed with medulloblastoma who underwent surgical resection followed by radiation therapy. Both patients underwent 24 cycles of chemotherapy with temozolamide over a period of 2 years with minimal toxicity. They were monitored with multiple MRIs of brain which have not revealed any disease recurrence so far rendering one patient disease free for eight and a half years and the other for six months. Very few cases of medulloblastoma treated with temozolamide have been reported. Our case series shows the antitumor effect of temozolamide in treatment of medulloblastoma with minimal toxicity. Most of the literature is based on retrospective analysis rather than randomized studies due to the small number of adult cases reported with this disease compared to the pediatric population. The optimal treatment regimen is not well established for this tumor and because of its rarity a multi-institutional clinical trial will be necessary to define the best treatment.
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.